2023

13/01/2023 IntegraGen reports 2022 revenue and cash position

2022

18/10/2022
IntegraGen reports strong revenues growth of 35% with profitability improvement
13/07/2022
IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€
29/04/2022
IntegraGen reports 2021 annual results with a strong growth of 20% in revenue from current operations and a significant profitability improvement
14/01/2022 IntegraGen reports 2021 revenue and cash position

2021

08/10/2021
IntegraGen reports results for first half of 2021
16/07/2021
IntegraGen reports sales of 4.8 M€ for the first half of 2021, a 2% increase versus 2020, and a cash position of 4.3 M€
16/04/2021 IntegraGen reports 2020 annual results: 10% growth in revenue from current operations and achievement of breakeven operating profits
12/01/2021  IntegraGen reports 2020 revenue and cash position

2020

18/09/2020 IntegraGen reports results for first half of 2020
09/07/2020 Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen
03/04/2020 IntegraGen reports 2019 annual results
26/03/2020 IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool
11/03/2020 IntegraGen renews its agreement with the Institut Pasteur
10/01/2020 IntegraGen reports 2019 revenue and cash position

2019

23/09/2019 IntegraGen announces 2019 first half results: Continued improvement in profitability
11/07/2019 IntegraGen reports sales of € 4.2 million in the first half of 2019, up 15%
18/04/2019 IntegraGen Reports 2018 Annual Results
05/03/2019 IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test
09/01/2019 IntegraGen reports 2018 revenue and cash position

2018

11/12/2018 IntegraGen announces collaboration with Google Cloud to offer large scale genomic analysis tools for clinicians and medical researchers
9/20/2018 IntegraGen Reports Financial Results for 1st Half of 2018
9/4/2018 IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research
7/31/2018 The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan
07/09/2018 IntegraGen Reports 17% Revenue Growth During First Half of 2018
04/23/2018 IntegraGen achieves ISO 13485:2016 certification for the design, manufacturing and distribution of In Vitro diagnostic kits
04/13/2018 IntegraGen reports 2017 annual results: Continued strength in clinical genomic services and improved net income
04/12/2018 IntegraGen presents data from liquid biopsy studies of proprietary miRNAs in lung cancer at during 2018 European Lung Cancer Conference (ELCC)
02/14/2018 IntegraGen and Twist Bioscience Expand Partnership with Distribution Agreement for SIRIUS and MERCURY Genomic Data Analysis Tools
01/25/2018 IntegraGen Partners with Twist Bioscience
01/18/2018 IntegraGen IntegraGen Launches SIRIUS™ and MERCURY™ – Big Data Tools for Exploration of Large-Scale Genomic Data
01/09/2018 IntegraGen reports 2017 revenue and cash position

2017

10/30/2017 IntegraGen Receives Galien MedStartUp Award for Their Collaboration with The Solution Lab on ICE Genomic Software Interpretation Tool
10/09/2017 IntegraGen announces publication of miR-31-3p data in Oncotarget 
09/28/2017 IntegraGen Reports Financial Results for 1st Half of 2017
09/07/2017 IntegraGen announces CE-IVD Marking of miRpredX 31-3p kit
07/11/2017 IntegraGen reports continued growth during 1st half of 2017
04/21/2017 IntegraGen announces 2016 Financial Results
03/08/2017 Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p test
02/03/2017 Integragen announces successfull completion of a € 3.7 million capital increase
01/09/2017 IntegraGen reports sharp increase in sales in 2016

2016

10/14/2016 IntegraGen reports revenues for first half of 2016
10/10/2016 New Data on IntegraGen’s miR-31-3p Biomarker Featured in Presentation at 2016 ESMO Congress
07/07/2016 IntegraGen reports strong revenue growth during first half of 2016
06/29/2016 AP-HP and IntegraGen Agree to a Research Partnership to Develop a Common Platform for High-Throughput Sequencing
06/06/2016 IntegraGen Presents Positive Data at 2016 ASCO Meeting on the Role of microRNA Biomarker miR-31-3p
04/08/2016 IntegraGen Announces 2015 Financial Results
01/14/2016 IntegraGen Reports 2015 Revenue

2015

12/02/2015 IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
11/17/2015 Gustave Roussy and IntegraGen announce completion of one thousand analyses on clinical research sequencing platform
10/02/2015 IntegraGen announces H1 2015 results
08/25/2015 IntegraGen sequencing of 193 liver tumor exomes published in Nature Genetics
07/10/2015 IntegraGen Reports Revenue for First Half of 2015
07/08/2015 AP-HP: Georges Pompidou European Hospital and IntegraGen sign agreement
06/01/2015 IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015
04/10/2015 IntegraGen Announces 2014 Financial Results
03/24/2015 The Institut Pasteur Announces an Alliance with IntegraGen to Strengthen its High-Throughput Sequencing Activities in Microbiology
02/05/2015 IntegraGen Announces Distribution Agreement for Autism Risk Assessment Test

2014

12/16/2014 IntegraGen Collaborating with PICCOLO Study Investigators to Validate Hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
12/02/2014 IntegraGen Obtains Exclusive Worldwide License for Two Molecular Signatures for Patients with Liver Cancer
10/07/2014 IntegraGen Reports First Half 2014 Financial Results
09/30/2014 IntegraGen Presents Data at ESMO 2014 Confirming that its microRNA Biomarker Predicts Survival in Patients with Metastatic Colorectal Cancer
09/02/2014 IntegraGen Announces Collaboration with the French Intergroup of Thoracic Oncology (IFCT)
to Explore the Role of miR‐31‐3p Biomarker in Non‐Small Cell Lung Cancer
06/23/2014 IntegraGen, Gustave Roussy, INSERM and Sogeti High Tech Announce Collaborative Development of an Advanced Scientific Software Program to Assist with the Interpretation of Genome Sequencing Data for Cancer Patients
06/02/2014 IntegraGen Presents Data at ASCO 2014 Annual Meeting on microRNA Biomarker Which Predicts Outcomes in Metastatic Colorectal Cancer Patients
05/19/2014 IntegraGen Presents Data on New Version of the ARISk® Test during the 13th Annual Meeting for Autism Research
05/15/2014 IntegraGen Announces Publication of Study with Biomarker Associated with Survival in Metastatic Colorectal Cancer Patients Treated with Drug Therapy
04/11/2014 IntegraGen Announces 2013 Annual Results
04/03/2014 IntegraGen Announces Collaborative Agreement with Pfizer to Evaluate IntegraGen’s Proprietary Hepatocellular Carcinoma Molecular Signature
03/24/2014 IntegraGen and Gustave Roussy Announce the Set-up of a High-Throughput Clinical Sequencing Unit
02/21/2014 IntegraGen Announces Publication of Study Which Supports the Association of Common Genetic Variants in the Development of Autism
01/14/2014 IntegraGen Collaborating with New EPOC Study Investigators to Validate Metastatic Colorectal Cancer Biomarker

Archived Press Releases 2013 / 2012